March 4, 2024

PPMD Hosts Town Hall on Clinical Trials During 2024 Advocacy Conference

The PPMD Town Hall on Clinical Trials, taking place on Monday, March 4th during PPMD’s 2024 Advocacy Conference in Washington, D.C., aims to provide a platform for families affected by Duchenne and Becker to share…

Learn More

January 30, 2024

Watch: Navigating Steroid Choices – Understanding the Process, Pathways, and Policies (Webinar Recording)

Last week, PPMD was joined by Kathy Mathews, MD (Neurologist), Christina Trout, RN, MSN (Clinic Coordinator), and Rachel Kinn, PharmD, BCPPS (Pharmacist) from the University of Iowa to discuss decision making regarding steroids. In recent…

Learn More

January 29, 2024

PPMD 2023 Duchenne Early Care Meeting Report Published: Enhancing Support in Early Diagnosis

Last year, PPMD hosted a Duchenne Early Care meeting as part of the 2023 Duchenne Healthcare Professionals Summit, focusing on key aspects of care for the youngest children in our Duchenne community, in preparation for…

Learn More

January 17, 2024

PPMD Hosts 2024 Duchenne Healthcare Professionals Summit

Each January, PPMD brings together experts in the field for our Duchenne Healthcare Professionals Summit to ensure that caring for individuals with the latest information and technology remains a constant priority.  Healthcare professionals from PPMD’s…

Learn More

January 11, 2024

Introducing PPMD’s Gene Therapy Hub

We are excited to announce the launch of PPMD’s Gene Therapy Hub! Gene therapy has made significant strides in Duchenne, with one therapy approved and other potential therapies in various stages of development. As our…

Learn More

January 9, 2024

Join us at PPMD’s 30th year meetings and events

Happy New Year! As PPMD celebrates its 30th anniversary in 2024, we’re thrilled to announce the expansion of our events and meetings dedicated to accelerating research, enhancing care and quality of life, and fostering connections…

Learn More

January 8, 2024

PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51

PepGen has announced that the first participant has been dosed in its Phase 2 CONNECT1-EDO51 study, which will evaluate the safety and tolerability of PGN-EDO51, the company’s next-generation conjugated-PMO exon skipping therapy for the treatment…

Learn More

January 6, 2024

Race to End Duchenne Celebrates Runners During Walt Disney World Marathon Weekend

The Race to End Duchenne team is in The Most Magical Place on Earth this weekend to participate in Walt Disney World® Marathon Weekend, presented by State Farm. Make Every Day Count  Michael (Mike) Napoli,…

Learn More

January 5, 2024

The Importance of Assisted Cough

It’s winter, which means respiratory virus season is upon us. Those living with Duchenne and Becker may find themselves needing more support to help clear thick secretions that often accompany respiratory illness. Using assisted cough…

Learn More

January 3, 2024

Thank You for Fighting for Every Future With Us

As we enter the New Year, my heart is filled with profound gratitude as I am once again reminded of the immense generosity of our Duchenne community. For the past three decades, you have supported…

Learn More